Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate

Trial Profile

Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Docetaxel; Etoposide
  • Indications Bladder cancer; Neuroendocrine carcinoma; Prostate cancer; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Jan 2019 Status changed from not yet recruiting to recruiting.
    • 10 Aug 2018 Planned End Date changed from 27 Jun 2021 to 1 Sep 2021.
    • 10 Aug 2018 Planned primary completion date changed from 27 Jun 2020 to 1 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top